# A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

> **NCT07541170** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 400 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Divarasib
- **DRUG:** Pembrolizumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT07541170
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2032-01-31
- **Final completion:** 2035-03-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07541170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07541170, "A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07541170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*